Rigel Pharmaceuticals has been granted a patent for IRAK inhibitors, specifically oxazole compounds, for treating or preventing IRAK-associated diseases. The patent also covers methods of making and using these compounds. GlobalData’s report on Rigel Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Rigel Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. Rigel Pharmaceuticals's grant share as of May 2024 was 43%. Grant share is based on the ratio of number of grants to total number of patents.
The granted patent (Publication Number: US11993594B2) discloses a compound with a specific chemical formula and structure, as outlined in various claims. The compound includes different configurations and substitutions, such as pyridinyl, pyrimidinyl, or pyrazinyl groups, as well as specific arrangements of atoms within the molecule. Additionally, the patent covers compositions containing the compound and methods for treating diseases or inhibiting specific proteins in subjects by administering the compound or compositions containing it.
Furthermore, the patent details the use of the compound for treating diseases or conditions in subjects by administering a therapeutically effective amount of the compound or a composition containing it. Specifically, the compound is highlighted for its potential in inhibiting IRAK in subjects, with a focus on administering the compound to target the IRAK protein in the subject. The patent provides a comprehensive overview of the compound's structure, variations, and applications in pharmaceutical compositions for therapeutic purposes, emphasizing its potential in treating various diseases and conditions by targeting specific proteins in the body.
To know more about GlobalData’s detailed insights on Rigel Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
